Dr. Henrik Luessen comes to Promethera as the Founder and Managing Director of Tytonis BV, based in The Netherlands. At Promethera, Henrik serves as Chief Business Officer where he is responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
In the past, Henrik was involved in the foundation to trade sale of several life science firms such as Symbiotec GmbH, Nanomi BV and Activaero GmbH. He also served as Chief Business Officer at OctoPlus NV until its initial public offering in 2006. During his time at OctoPlus, Henrik commercially developed the company from a group of 12 employees with a core expertise in pharmaceutical development of biopharmaceutical compounds to an organization of 140 people with two proprietary products in clinical development. During his career he has concluded around 250 IP-related, transactional and licensing deals.
Henrik obtained his PhD in Pharmaceutics and Biopharmaceutics from the Leiden/Amsterdam Center for Drug Research in 1996 and graduated at the University of Hamburg as Pharmacist in 1991.